Review of teriflunomide and its potential in the treatment of multiple sclerosis
نویسندگان
چکیده
In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.
منابع مشابه
P 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...
متن کاملImmunomodulatory Effect of Mesenchymal Stem Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: A Review Study
Multiple Sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system that may lead to disability of the patient. Current MS treatment regimens are still insufficient and research is conducted for developing more effective therapies capable of targeting neurodegeneration, inflammation, and demyelination. Recent results of experimental and clinical studies in ...
متن کاملAn update of teriflunomide for treatment of multiple sclerosis
There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. This review w...
متن کاملRole of oral teriflunomide in the management of multiple sclerosis
The landscape of the treatment of relapsing-remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing-remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for...
متن کاملTeriflunomide and Its Mechanism of Action in Multiple Sclerosis
Treatment of multiple sclerosis (MS) is challenging: disease-modifying treatments (DMTs) must both limit unwanted immune responses associated with disease initiation and propagation (as T and B lymphocytes are critical cellular mediators in the pathophysiology of relapsing MS), and also have minimal adverse impact on normal protective immune responses. In this review, we summarize key preclinic...
متن کاملOral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience
Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-daily, oral immunomodulatory therapy, has demonstrated efficacy across multiple measures of disease activity and worsening in patients with relapsin...
متن کامل